Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1430798
This article is part of the Research Topic Advances in precision medicine in the management of thyroid nodules and thyroid cancer View all 24 articles

Causal validation of the relationship between 35 blood and urine biomarkers and hyperthyroidism: A bidirectional Mendelian randomization study and meta-analysis

Provisionally accepted
Wanxian Xu Wanxian Xu Jiao Wu Jiao Wu Daolei Chen Daolei Chen Rui Zhang Rui Zhang Yang Yue Yang Yue *
  • Department of Breast and Thyroid Surgery, First People's Hospital of Kunming City & Calmette Affiliated Hospital of Kunming Medical University,1228 Beijing Road, Kunming 650032, Yunnan, China, Kunming, Yunnan Province, China

The final, formatted version of the article will be published soon.

    Abstract Background Hyperthyroidism is an endocrine disorder with a relatively low global prevalence but significantly higher incidence among females compared to males. The onset age primarily ranges from 30 to 50, although it is not limited to this age group. Challenges in the treatment of hyperthyroidism include individualized treatment plan formulation, management of side effects, and prediction of disease progression, necessitating comprehensive consideration to achieve more effective therapy and management. Mendelian randomization studies can reveal more precise therapeutic targets between blood and urine biomarkers and hyperthyroidism, providing more decadent treatment options for the condition. Methods The study will build upon the omics Mendelian randomization (MR) framework by conducting MR analysis using 35 blood and urine biomarkers separately for two distinct databases of hyperthyroidism. Subsequently, the results will undergo meta-analysis and multiple corrections to ensure accuracy and reliability. Finally, positive findings will undergo reverse MR validation to verify causal relationships with hyperthyroidism. Results In the British database, the MR analysis of Total bilirubin levels about hyperthyroidism yielded an odds ratio (OR) of 1.097 (95% CI: 0.951-1.265, P = 0.205). Conversely, in the Thyroid Omics Association database, the MR analysis revealed an OR of 1.283 (95% CI: 1.122-1.467, P = 0.0002) for the same relationship. Meta-analysis of the MR analysis results from both databases, following multiple corrections, resulted in an OR of 1.192 (95% CI: 1.081-1.314, P = 0.015). Additionally, the direction of beta values in the MR analysis results from both databases was consistent. Conclusions The urine biomarker total bilirubin levels may contribute to an increased risk of hyperthyroidism and accelerate its progression, thus representing a risk factor for the condition.

    Keywords: blood and urine biomarkers 1, hyperthyroidism 2, mendelian randomization analysis3, meta-analysis4, authenticate reverse5, multiple corrections6

    Received: 10 May 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 Xu, Wu, Chen, Zhang and Yue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yang Yue, Department of Breast and Thyroid Surgery, First People's Hospital of Kunming City & Calmette Affiliated Hospital of Kunming Medical University,1228 Beijing Road, Kunming 650032, Yunnan, China, Kunming, Yunnan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.